WHAT IS CLAIMED IS:

1. A pharmaceutical or cosmetic carrier comprising, by weight, 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent.

2. The pharmaceutical or cosmetic carrier of claim 1, wherein said solidifying agent is selected from the group consisting of at least one long chain fatty alcohol having at least 15 carbon atoms in its carbon backbone and at least one fatty acid, having at least 18 carbon atoms in its carbon backbone.

3. The pharmaceutical or cosmetic carrier of claim 1, wherein said solidifying agent includes a substance selected such that under ambient conditions, the carrier is semi-solid at rest and liquefies upon application of shear forces thereto.

4. The pharmaceutical or cosmetic carrier of claim 1, wherein said hydrophobic solvent is selected from the group consisting of at least

one marine animal derived oil, at least one terrestrial animal derived oil, at least one mineral oil, at least one silicone oil and at least one plant-derived oil.

5. The pharmaceutical or cosmetic carrier of claim 1, wherein said hydrophobic solvent includes an oil selected from the group consisting of olive oil, soybean oil, canola oil, rapeseed oil, cottonseed oil, coconut oil, palm oil, sesame oil, sunflower oil, safflower oil, rice bran oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, corn oil, flaxseed oil, wheat germ oil, rape seed oil, evening primrose oil, rosehip oil, tea tree oil, melaleuca oil and jojova oil.

6. The pharmaceutical or cosmetic carrier of claim 1, wherein said hydrophobic solvent includes an oil selected from the group consisting of omega-3 oil and omega-6 oil.

7. The pharmaceutical or cosmetic carrier of claim 2, wherein said solidifying agent has at least one alkyl group side chain in its carbon backbone.

8. The pharmaceutical or cosmetic carrier or composition of claim 2, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at position α and β.

9. The pharmaceutical or cosmetic carrier of claim 2, wherein said carbon backbone of said fatty alcohol has at least one hydroxyl group at position α and β.

10. The pharmaceutical or cosmetic carrier of claim 2, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at positions 8-14.

11. The pharmaceutical or cosmetic carrier of claim 2, wherein said solidifying agent includes a 12-hydroxy fatty acid.

12. The pharmaceutical or cosmetic carrier of claim 1, wherein at least one of said solidifying agent and said hydrophobic solvent has a therapeutic or cosmetic beneficial effect.

13. A method of preparing a pharmaceutical or cosmetic carrier, the method comprising the steps of:

(a) mixing a hydrophobic solvent and a solidifying agent at a temperature above a melting temperature of said solidifying agent so as to obtain a mixture containing 75-99 percent of said hydrophobic solvent by weight and 1-25 percent of said solidifying agent by weight; and

(b) cooling the mixture.

14. The method of claim 13, wherein prior to said step of mixing, both said hydrophobic solvent and said solidifying agent are brought to said temperature above said melting temperature of said solidifying agent.

15. The method of claim 13, wherein said solidifying agent is selected from the group consisting of at least one long chain fatty alcohol having at least 15 carbon atoms in its carbon backbone and at least one fatty acid, having at least 18 carbon atoms in its carbon backbone.

16. The method of claim 13, wherein said solidifying agent includes a substance selected such that under ambient conditions, the carrier is semi-solid at rest and liquefies upon application of shear forces thereto.

17. The method of claim 13, wherein said hydrophobic solvent is selected from the group consisting of at least one marine animal derived oil, at least one terrestrial animal derived oil, at least one mineral oil, at least one silicone oil and at least one plant-derived oil.

18. The method of claim 13, wherein said hydrophobic solvent includes an oil selected from the group consisting of olive oil, soybean oil, canola oil, rapeseed oil, cottonseed oil, coconut oil, palm oil, sesame oil, sunflower oil, safflower oil, rice bran oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, corn oil, flaxseed oil, wheat germ oil, rape seed oil, evening primrose oil, rosehip oil, tea tree oil, melaleuca oil and jojova oil.

19. The method of claim 13, wherein said hydrophobic solvent includes an oil selected from the group consisting of omega-3 oil and omega-6 oil.

20. The method of claim 15, wherein said solidifying agent has at least one alkyl group side chain in its carbon backbone.

21. The method of claim 15, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at position α and β.

22. The method of claim 15, wherein said carbon backbone of said fatty alcohol has at least one hydroxyl group at position α and β.

23. The method of claim 15, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at positions 8-14.

24. The method of claim 15, wherein said solidifying agent includes a 12-hydroxy fatty acid.

25. The method of claim 13, wherein at least one of said solidifying agent and said hydrophobic solvent has a therapeutic or cosmetic beneficial effect.

26. A pharmaceutical or cosmetic composition comprising, by weight, 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, wherein at least one of said solidifying agent and said hydrophobic solvent has a therapeutic or cosmetic beneficial effect.

27. The pharmaceutical or cosmetic composition of claim 26, wherein said solidifying agent is selected from the group consisting of at least one long chain fatty alcohol having at least 15 carbon atoms in its carbon backbone and at least one fatty acid, having at least 18 carbon atoms in its carbon backbone.

28. The pharmaceutical or cosmetic composition of claim 26, wherein said solidifying agent includes a substance selected such that under ambient conditions, the carrier is semi-solid at rest and liquefies upon application of shear forces thereto.

29. The pharmaceutical or cosmetic composition of claim 26, wherein said hydrophobic solvent is selected from the group consisting of at least one marine animal derived oil, at least one terrestrial animal derived oil, at least one mineral oil, at least one silicone oil and at least one plant-derived oil.

30. The pharmaceutical or cosmetic composition of claim 26, wherein said hydrophobic solvent includes an oil selected from the group consisting of olive oil, soybean oil, canola oil, rapeseed oil, cottonseed oil, coconut oil, palm oil, sesame oil, sunflower oil, safflower oil, rice bran oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, corn oil, flaxseed oil, wheat germ oil, rape seed oil, evening primrose oil, rosehip oil, tea tree oil, melaleuca oil and jojova oil.

31. The pharmaceutical or cosmetic composition of claim 26, wherein said hydrophobic solvent includes an oil selected from the group consisting of omega-3 oil and omega-6 oil.

32. The pharmaceutical or cosmetic composition of claim 26, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at position α and β.

33. The pharmaceutical or cosmetic composition of claim 26, wherein said carbon backbone of said fatty alcohol has at least one hydroxyl group at position α and β.

34. The pharmaceutical or cosmetic composition of claim 26, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at positions 8-14.

35. The pharmaceutical or cosmetic composition of claim 26, wherein said solidifying agent includes a 12-hydroxy fatty acid.

36. The pharmaceutical or cosmetic composition of claim 26, wherein said carbon backbone of said fatty alcohol has at least one hydroxyl group at position α and β.

37. A pharmaceutical or cosmetic composition comprising:

(a) a pharmaceutical or cosmetic carrier containing, by weight, 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent; and

(b) a therapeutically or cosmetically effective amount of a biologically active substance.

38. The pharmaceutical or cosmetic composition of claim 37, wherein said solidifying agent is selected from the group consisting of at least one long chain fatty alcohol having at least 15 carbon atoms in its carbon backbone and at least one fatty acid, having at least 18 carbon atoms in its carbon backbone.

39. The pharmaceutical or cosmetic composition of claim 37, wherein said solidifying agent includes a substance selected such that

under ambient conditions, the carrier is semi-solid at rest and liquefies upon application of shear forces thereto.

40. The pharmaceutical or cosmetic composition of claim 37, wherein said hydrophobic solvent is selected from the group consisting of at least one marine animal derived oil, at least one terrestrial animal derived oil, at least one mineral oil, at least one silicone oil and at least one plant-derived oil.

41. The pharmaceutical or cosmetic composition of claim 38, wherein said hydrophobic solvent includes an oil selected from the group consisting of olive oil, soybean oil, canola oil, rapeseed oil, cottonseed oil, coconut oil, palm oil, sesame oil, sunflower oil, safflower oil, rice bran oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, corn oil, flaxseed oil, wheat germ oil, rape seed oil, evening primrose oil, rosehip oil, tea tree oil, melaleuca oil and jojova oil.

42. The pharmaceutical or cosmetic composition of claim 37, wherein said hydrophobic solvent includes an oil selected from the group consisting of omega-3 oil and omega-6 oil.

43. The pharmaceutical or cosmetic composition of claim 37, wherein said solidifying agent has at least one alkyl group side chain in its carbon backbone.

44. The pharmaceutical or cosmetic composition of claim 38, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at position α and β.

45. The pharmaceutical or cosmetic composition of claim 38, wherein said carbon backbone of said fatty alcohol has at least one hydroxyl group at position α and β.

46. The pharmaceutical or cosmetic composition claim 38, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at positions 8-14.

47. The pharmaceutical or cosmetic composition of claim 38, wherein said solidifying agent includes a 12-hydroxy fatty acid.

48. The pharmaceutical or cosmetic composition of claim 37, wherein at least one of said solidifying agent and said hydrophobic solvent has a therapeutic or cosmetic beneficial effect.

49. The pharmaceutical or cosmetic composition of claim 37, wherein said biologically active substance is selected from the group of consisting of an antibiotic agent, a free radical generating agent, an antifungal agent, an antiviral agent, a non-nucleoside reverse transcriptase inhibitor, a nucleoside-analog reverse transcriptase inhibitor, a protease inhibitor, a non-steroidal antiinflammatory drug, an immunosuppressant, an antihistamine agent, an antiinflammatory agent, a retinoid agent, a tar agent, an antipruritics agent and a scabicide agent.

50. The pharmaceutical or cosmetic composition of claim 49, wherein:

(a) said antibiotic agent is selected from the group consisting of chloramphenicol, tetracyclines, synthetic and semi-synthesic penicillins, beta-lactames, quinolones, fluoroquinolnes, macrolide antibiotics, peptide antibiotics, cyclosporines, erytromycin and clinndamycin;

(b) said free radical generating agent is benzoyl peroxide;

(c) said antifungal agent is selected from the group consisting of azoles, diazoles, triazoles, miconazole, fluconazole, ketoconazole, clotrimazol, itraconazole griseofulvin, ciclopirox, amorolfine, terbinafine, Amphotericin B and potassium iodide;

(d) said antiviral agent is selected from the group consisting of flucytosine (5FC), Vidarabine, acyclovir and Gancyclovir;

(e) said nucleoside-analog reverse transcriptase inhibitor is selected from the group consisting of Zidovudine, Stavudine and Lamivudine;

(f) said non-nucleoside reverse transcriptase inhibitor is selected from the group consisting of Nevirapine and Delavirdine;

(g) said protease inhibitor is selected from the group consisting of Saquinavir, Ritonavir, Indinavir, Nelfinavir, Ribavirin Amantadine, Rimantadine and Interferon;

(h) said immunosuppressant is selected from the group consisting of Clobetasol proprionate, Halobetasol proprionate, Betamethasone diproprionate, Betamethasone valerate, Fluocinolone acetonide, Halcinonide, Betamethasone valerate, Fluocinolone acetonide, Hydrocortisone valerate, Triamcinolone acetonide, Hydrocortisone and hexachlorobenzene;

(i) said antiinflammatory agent is a vitamin B3 or a derivative thereof;

(j) said retinoid agent is selected from the group consisting of isotretinoin, adapalene and tretinoin;

(k) said tar agent is selected from the group consisting of coal tar and cade oil;

(l) said antihistamine agent is doxepine hydrochloride;

(m) said antipruritic agent is crotampiton; and

(n) said scabicide agent is selected from the group consisting of benzyl benzoate, malathion and crotamiton.

51. The pharmaceutical or cosmetic composition of claim 37, wherein said biologically active substance is effective in the treatment of a disease or disorder selected from the group consisting of psoriasis, acne, seborrhea, seborrheic dermatitis, alopecia and excessive hair growth, ichthyosis, wounds, burns, cuts, ulcers, psoriasis, seborrheic dermatitis of the face and trunk, seborrheic blepharitis, contact dermatitis, stasis dermatitis and exfoliative dermatitis.

52. The pharmaceutical or cosmetic composition of claim 51, wherein said statis dermatitis is selected from the group consisting of gravitational eczema, varicose eczema and further wherein said exfoliative dermatitis is erythroderma.

53. A method of preparing a pharmaceutical or cosmetic composition, the method comprising the steps of

(a) mixing a hydrophobic solvent and a solidifying agent at a temperature above a melting temperature of said solidifying agent so as to obtain a pharmaceutical or cosmetic mixture containing 75-99 percent of said hydrophobic solvent by weight and 1-25 percent of said solidifying agent by weight; and

(b) further mixing into said carrier mixture a therapeutically or cosmetically effective amount of a biologically active substance.

54. The method of claim 53, wherein prior to said step of mixing, both said hydrophobic solvent and said solidifying agent are brought to said temperature above said melting temperature of said solidifying agent.

55. The method of claim 53, wherein said solidifying agent is selected from the group consisting of at least one long chain fatty alcohol having at least 15 carbon atoms in its carbon backbone and at least one fatty acid , having at least 18 carbon atoms in its carbon backbone.

56. The method of claim 53, wherein said solidifying agent includes a substance selected such that under ambient conditions, the carrier is semi-solid at rest and liquefies upon application of shear forces thereto.

57. The method of claim 53, wherein said hydrophobic solvent is selected from the group consisting of at least one marine animal derived oil, at least one terrestrial animal derived oil, at least one mineral oil, at least one silicone oil and at least one plant-derived oil.

58. The method of claim 53, wherein said hydrophobic solvent includes an oil selected from the group consisting of olive oil, soybean oil, canola oil, rapeseed oil, cottonseed oil, coconut oil, palm oil, sesame oil, sunflower oil, safflower oil, rice bran oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, corn oil, flaxseed oil, wheat germ oil, rape seed oil, evening primrose oil, rosehip oil, tea tree oil, melaleuca oil and jojova oil.

59. The method of claim 53, wherein said hydrophobic solvent includes an oil selected from the group consisting of omega-3 oil and omega-6 oil.

60. The method of claim 53, wherein said solidifying agent has at least one alkyl group side chain in its carbon backbone.

61. The method of claim 55, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at position α and β.

62. The method of claim 55, wherein said carbon backbone of said fatty alcohol has at least one hydroxyl group at position α and β.

63. The method of claim 55, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at positions 8-14.

64. The method of claim 55, wherein said solidifying agent includes a 12-hydroxy fatty acid.

65. The method of claim 53, wherein at least one of said solidifying agent and said hydrophobic solvent has a therapeutic or cosmetic beneficial effect.

66. The method of claim 53, wherein said biologically active substance is selected from the group of consisting of an antibiotic agent, a free radical generating agent, an antifungal agent, an antiviral agent, a non-nucleoside reverse transcriptase inhibitor, a nucleoside-analog reverse transcriptase inhibitor, a protease inhibitor, a non-steroidal antiinflammatory drug, an immunosuppressant, an antihistamine agent, an antiinflammatory agent, a retinoid agent, a tar agent, an antipruritics agent and a scabicide agent.

67. The method of claim 66, wherein:

(a) said antibiotic agent is selected from the group consisting of chloramphenicol, tetracyclines, synthetic and semi-synthesic

penicillins, beta-lactames, quinolones, fluoroquinolnes, macrolide antibiotics, peptide antibiotics, cyclosporines, erytromycin and clinndamycin;

(b) said free radical generating agent is benzoyl peroxide;

(c) said antifungal agent is selected from the group consisting of azoles, diazoles, triazoles, miconazole, fluconazole, ketoconazole, clotrimazole, itraconazole griseofulvin, ciclopirox, amorolfine, terbinafine, Amphotericin B and potassium iodide;

(d) said antiviral agent is selected from the group consisting of flucytosine (5FC), Vidarabine, acyclovir and Gancyclovir;

(e) said nucleoside-analog reverse transcriptase inhibitor is selected from the group consisting of Zidovûdine, Stavudine and Lamivudine;

(f) said non-nucleoside reverse transcriptase inhibitor is selected from the group consisting of Nevirapine and Delavirdine;

(g) said protease inhibitor is selected from the group consisting of Saquinavir, Ritonavir, Indinavir, Nelfinavir, Ribavirin Amantadine, Rimantadine and Interferon;

(h) said immunosuppressant is selected from the group consisting of Clobetasol proprionate, Halobetasol proprionate, Betamethasone diproprionate, Betamethasone valerate, Fluocinolone acetonide, Halcinonide, Betamethasone valerate, Fluocinolone acetonide, Hydrocortisone valerate, Triamcinolone acetonide, Hydrocortisone and hexachlorobenzene;

(i) said antiinflammatory agent is a vitamin B3 or a derivative thereof;

(j) said retinoid agent is selected from the group consisting of isotretinoin, adapalene and tretinoin;

(k) said tar agent is selected from the group consisting of coal tar and cade oil;

(l) said antihistamine agent is doxepine hydrochloride;

(m) said antipruritic agent is crotampiton; and

(n) said scabicide agent is selected from the group consisting of benzyl benzoate, malathion and crotamiton.

68. The method of claim 53, wherein said biologically active substance is effective in the treatment of a disease or disorder selected from the group consisting of psoriasis, acne, seborrhea, seborrheic dermatitis, alopecia and excessive hair growth, ichthyosis, wounds, burns, cuts, ulcers, psoriasis, seborrheic dermatitis of the face and trunk, seborrheic blepharitis, contact dermatitis, stasis dermatitis and exfoliative dermatitis.

69. The method of claim 68, wherein said statis dermatitis is selected from the group consisting of gravitational eczema, varicose eczema and further wherein said exfoliative dermatitis is erythroderma.

70. A method of treating a disease or disorder of a skin or a mucosal membrane comprising the step of topically administrating to said skin or said mucosal membrane a pharmaceutical or cosmetic composition containing, by weight, 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, wherein at least one of said solidifying agent and said hydrophobic solvent has a therapeutic or cosmetic beneficial effect.

71. The method of claim 70, wherein said disease or disorder is selected from the group consisting of psoriasis, acne, seborrhea, seborrheic dermatitis, alopecia and excessive hair growth, ichthyosis, wounds, burns, cuts, ulcers, psoriasis, seborrheic dermatitis of the face and trunk, seborrheic blepharitis, contact dermatitis, stasis dermatitis and exfoliative dermatitis.

72. The method of claim 71, wherein said statis dermatitis is selected from the group consisting of gravitational eczema, varicose eczema and further wherein said exfoliative dermatitis is erythroderma.

73. The method of claim 70, wherein said mucosal membrane is selected from the group consisting of a mucosa of a nose, a mucosa of a mouth, a mucosa of an eye, a mucosa of an ear, a mucosa of a vagina and mucosa of a rectum.

74. The method of claim 70, wherein said disease or disorder is an inflammation caused by an inflammatory agent selected from the group consisting of a bacterial inflammatory agent, a fungal inflammatory agent,

a viral inflammatory agent, a parasitic inflammatory agent, an autoimmune inflammatory agent, an allergic inflammatory agent, a hormonal inflammatory agent and a malignant inflammatory agent.

75. The method of claim 70, wherein said solidifying agent is selected from the group consisting of at least one long chain fatty alcohol having at least 15 carbon atoms in its carbon backbone and at least one fatty acid, having at least 18 carbon atoms in its carbon backbone.

76. The method of claim 70, wherein said solidifying agent includes a substance selected such that under ambient conditions, the carrier is semi-solid at rest and liquefies upon application of shear forces thereto.

77. The method of claim 70, wherein said hydrophobic solvent is selected from the group consisting of at least one marine animal derived oils, at least one terrestrial animal derived oil, at least one mineral oils, at least one silicone oil and at least one plant-derived oils .

78. The method of claim 70, wherein said hydrophobic solvent includes an oil selected from the group consisting of olive oil, soybean oil, canola oil, rapeseed oil, cottonseed oil, coconut oil, palm oil, sesame oil, sunflower oil, safflower oil, rice bran oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, corn oil, flaxseed oil, wheat germ oil, rape seed oil, evening primrose oil, rosehip oil, tea tree oil, melaleuca oil and jojova oil.

79. The method of claim 70, wherein said hydrophobic solvent includes an oil selected from the group consisting of omega-3 oil and omega-6 oil.

80. The method of claim 70, wherein said solidifying agent has at least one alkyl group side chain in its carbon backbone.

81. The method of claim 80, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at position α and β.

82. The method of claim 80, wherein said carbon backbone of said fatty alcohol has at least one hydroxyl group at position α and β.

83. The method of claim 80, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at positions 8-14.

84. The method of claim 70, wherein said solidifying agent includes a 12-hydroxy fatty acid.

85. A method of treating a disease or disorder of a skin or a mucosal membrane comprising the step of topically administrating thereto a pharmaceutical or cosmetic composition containing:

(a) a pharmaceutical or cosmetic carrier containing, by weight, 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent; and

(b) a therapeutically or cosmetically effective amount of a biologically active substance.

86. The method of claim 85, wherein said mucosal membrane is selected from the group consisting of a mucosa of a nose, a mucosa of a mouth, a mucosa of an eye, a mucosa of an ear, a mucosa of a vagina and mucosa of a rectum.

87. The method of claim 85, wherein said solidifying agent is selected from the group consisting of at least one long chain fatty alcohol having at least 15 carbon atoms in its carbon backbone and at least one fatty acid, having at least 18 carbon atoms in its carbon backbone.

88. The method of claim 85, wherein said solidifying agent includes a substance selected such that under ambient conditions, the carrier is semi-solid at rest and liquefies upon application of shear forces thereto.

89. The method of claim 85, wherein said hydrophobic solvent is selected from the group consisting of at least one marine animal derived oils, at least one terrestrial animal derived oil, at least one mineral oil, at least one silicone oil and at least one plant-derived oil.

90. The method of claim 85, wherein said hydrophobic solvent includes an oil selected from the group consisting of olive oil, soybean oil, canola oil, rapeseed oil, cottonseed oil, coconut oil, palm oil, sesame oil, sunflower oil, safflower oil, rice bran oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, corn oil, flaxseed oil, wheat germ oil, rape seed oil, evening primrose oil, rosehip oil, tea tree oil, melaleuca oil and jojova oil.

91. The method of claim 85, wherein said hydrophobic solvent includes an oil selected from the group consisting of omega-3 oil and omega-6 oil.

92. The method of claim 85, wherein said solidifying agent has at least one alkyl group side chain in its carbon backbone.

93. The method of claim 87, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at position α and β.

94. The method of claim 87, wherein said carbon backbone of said fatty alcohol has at least one hydroxyl group at position α and β.

95. The method of claim 87, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at positions 8-14.

96. The method of claim 85, wherein said solidifying agent includes a 12-hydroxy fatty acid.

97. The method of claim 85, wherein said disease or disorder is inflammation caused by an inflammatory agent selected from the group consisting of a bacterial inflammatory agent, a fungal inflammatory agent, a viral inflammatory agent, a parasitic inflammatory agent, an autoimmune inflammatory agent, an allergic inflammatory agent, a hormonal inflammatory agent and a malignant inflammatory agent.

98. The method of claim 85, wherein said biologically active substance is effective in the treatment of a disease or disorder selected

from the group consisting of psoriasis, acne, seborrhea, seborrheic dermatitis, alopecia and excessive hair growth, ichthyosis, wounds, burns, cuts, ulcers, psoriasis, seborrheic dermatitis of the face and trunk, seborrheic blepharitis, contact dermatitis, stasis dermatitis and exfoliative dermatitis.

99. The method of claim 98, wherein said statis dermatitis is selected from the group consisting of gravitational eczema, varicose eczema and further wherein said exfoliative dermatitis is erythroderma.

100. The method of claim 85, wherein said disease or disorder is selected from the group consisting of psoriasis, acne, seborrhea, seborrheic dermatitis, alopecia and excessive hair growth, ichthyosis, wounds, burns, cuts, ulcers, psoriasis, seborrheic dermatitis of the face and trunk, seborrheic blepharitis, contact dermatitis, stasis dermatitis and exfoliative dermatitis.

101. The method of claim 100, wherein said statis dermatitis is selected from the group consisting of gravitational eczema, varicose eczema and further wherein said exfoliative dermatitis is erythroderma.

102. The method of claim 85, wherein said biologically active substance is selected from the group of consisting of an antibiotic agent, a free radical generating agent, an antifungal agent, an antiviral agent, a non-nucleoside reverse transcriptase inhibitor, a nucleoside-analog reverse transcriptase inhibitor, a nucleoside-analog reverse transcriptase inhibitor, a protease inhibitor, a non-steroidal antiinflammatory drug, an immunosuppressant, an antihistamine agent, an antiinflammatory agent, a retinoid agent, a tar agent, an antipruritics agent and a scabicide agent.

103. The method of claim 102, wherein:

(a) said antibiotic agent is selected from the group consisting of chloramphenicol, tetracyclines, synthetic and semi-synthesic penicillins, beta-lactames, quinolones, fluoroquinolnes, macrolide antibiotics, peptide antibiotics, cyclosporines, erytromycin and clinndamycin;

(b) said free radical generating agent is benzoyl peroxide;

(c) said antifungal agent is selected from the group consisting of azoles, diazoles, triazoles, miconazole, fluconazole, ketoconazole, clotrimazole, itraconazole griseofulvin, ciclopirox, amorolfine, terbinafine, Amphotericin B and potassium iodide;

(d) said antiviral agent is selected from the group consisting of flucytosine (5FC), Vidarabine, acyclovir and Gancyclovir;

(e) said nucleoside-analog reverse transcriptase inhibitor is selected from the group consisting of Zidovudine, Stavudine and Lamivudine;

(f) said non-nucleoside reverse transcriptase inhibitor is selected from the group consisting of Nevirapine and Delavirdine;

(g) said protease inhibitor is selected from the group consisting of Saquinavir, Ritonavir, Indinavir, Nelfinavir, Ribavirin Amantadine, Rimantadine and Interferon;

(h) said immunosuppressant is selected from the group consisting of Clobetasol proprionate, Halobetasol proprionate, Betamethasone diproprionate, Betamethasone

valerate, Fluocinolone acetonide, Halcinonide, Betamethasone valerate, Fluocinolone acetonide, Hydrocortisone valerate, Triamcinolone acetonide, Hydrocortisone and hexachlorobenzene;

(i) said antiinflammatory agent is a vitamin B3 or a derivative thereof;

(j) said retinoid agent is selected from the group consisting of isotretinoin, adapalene and tretinoin;

(k) said tar agent is selected from the group consisting of coal tar and cade oil;

(l) said antihistamine agent is doxepine hydrochloride;

(m) said antipruritic agent is crotampiton; and

(n) said scabicide agent is selected from the group consisting of benzyl benzoate, malathion and crotamiton.